SRR35579800
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.150
- PANCREAS_BETA_CELLS+0.150
- MYC_TARGETS_V1+0.140
- OXIDATIVE_PHOSPHORYLATION+0.110
- MYC_TARGETS_V2+0.100
- ESTROGEN_RESPONSE_EARLY+0.070
- SPERMATOGENESIS+0.060
- PEROXISOME+0.020
- BILE_ACID_METABOLISM+0.000
- MYOGENESIS-0.010
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.530
- INTERFERON_ALPHA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.510
- TNFA_SIGNALING_VIA_NFKB-0.480
- INFLAMMATORY_RESPONSE-0.470
- CHOLESTEROL_HOMEOSTASIS-0.440
- IL6_JAK_STAT3_SIGNALING-0.440
- COMPLEMENT-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- ANGIOGENESIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R16 | — | — | 0.901 |
| 2 | SRR4296068 | — | cohortA1 | 0.901 |
| 3 | SRR5088853 | — | — | 0.897 |
| 4 | SRR25617882 | — | B | 0.894 |
| 5 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.892 |
| 6 | SRR1394450 | GTEX | — | 0.891 |
| 7 | SRR1498702 | GTEX | — | 0.891 |
| 8 | SRR1319672 | GTEX | — | 0.890 |
| 9 | SRR1385036 | GTEX | — | 0.888 |
| 10 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |